Analyst at Morgan Stanley weighed in Moderna (NASDAQ: MRNA) RNA-based experimental seasonal flu vaccine and called it undifferentiated versus Fluzone ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE